Lv1
50 积分 2024-12-17 加入
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
3个月前
已完结
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. Eur J Cancer
3个月前
已完结
Mechanisms of oncolytic viruses reversing immunotherapy resistance: Focus on tumor microenvironment remodeling and immune memory. Cancer Immunol Immunother
4个月前
已关闭
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
4个月前
已完结
Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts)
8个月前
已关闭
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
9个月前
已完结
皖公网安备34019202002308
